There is ample evidence that the acute stress response is altered in schizophrenia and bipolar disorder. However, it is not clear whether such changes are related to the illness, a genetic vulnerability, or is the result of medication that is used in the majority of these patients. Therefore, we investigated determinants of the acute endocrine and autonomic stress response in healthy controls (n=48), euthymic BD1 patients (n=49) and unaffected siblings of BD1 patients (n=27). All participants completed a validated psychosocial stress task, the Trier Social Stress Test for Groups (TSST-G). Saliva levels of alpha-amylase and cortisol were measured before, during, and after exposure to stress. Compared to controls, we found a significantly blunted cortisol stress response in BD1 patients. Conversely, BD1 patients displayed exaggerated alpha-amylase levels in response to stress. Antipsychotic use was a significant contributing factor to the blunted cortisol stress response in BD1 patients. Unaffected BD1 siblings displayed similar stress-induced cortisol and alpha-amylase levels as controls, suggesting that familial risk for BD1 did not have a large effect on the functionality of the stress system. In conclusion, this study shows that euthymic BD1 patients have a substantially blunted endocrine stress response but an exaggerated autonomic stress response and that the endocrine stress response differences can be largely contributed to antipsychotic use rather than constitute a specific BD1 phenotype or vulnerability.
Introduction
In psychiatric disorders such as schizophrenia, bipolar disorder and major depressive disorder, blunted and increased stress responsivity have been reported (Brenner et al., 2009; Petrowski et al., 2013; Lange et al., 2013) . However, our understanding of the neurobiological background altered stress response in these disorders is limited. There are indications in BD1 patients that stress exposure results in a blunted endocrine stress response (Wieck et al., 2013) and reduced heart rate variability (Cohen et al., 2003) . BD1 patients also display an increased basal activity of the endocrine and autonomic systems as reflected by an increased cortisol awakening response (Cervantes et al., 2001 ) and increased basal sympathetic nervous system (SNS) activity (Lake et al., 1982) . Even though there are indications that stress system functionality is altered in BD1, it is currently unknown whether stress reactivity is consistently altered in BD1 patients and which factors may influence stress reactivity.
In other psychiatric populations, several factors have been identified that influence stress reactivity, including childhood maltreatment (Heim et al., 2000) , and the number of depressive episodes (Morris et al., 2012) . Investigating the influence of psychiatric medication such as antidepressants (Lange et al., 2013) and antipsychotics (Cohrs et al., 2006) is also relevant as these drugs can alter HPA axis activity. Moreover, multiple studies in healthy controls have clearly linked genetic markers to altered stress reactivity in the TSST task (see for example (van Leeuwen et al., 2011; DeRijk and de Kloet, 2008) ). In light of the high heritability of BD1 and alterations in the stress system, impaired stress system functionality in BD1 may also be the result of a genetic predisposition for BD1 (Ising and Holsboer, 2006) . If a genetic BD1 predisposition would result in altered stress reactivity, it is expected that unaffected adult siblings of BD1 patients, who on average share 50% of risk genes with probands, display a similar altered stress response.
This study aims to establish i) indices for both HPA-axis and ANS reactivity to stress in euthymic BD1 patients and ii) examine to what extent disease characteristics, medication, and genetic vulnerability contribute to aberrant stress reactivity of BD1 patients. To this end, we exposed euthymic BD1 patients to a group-wise Trier Social Stress Test (TSST-G), and compared this group to unrelated unaffected healthy siblings of BD1 patients and healthy controls.
Experimental procedures

Participants
Participants were eligible for participation if they had 3 or more Dutch grandparents and were fluent in Dutch, in view of the verbal test. Participants were instructed to refrain from heavy meals, drinks other than water and heavy exercise at least 2 h before the stress task, as well as to refrain from caffeine use at least 4 h before the experimental session. All participants reported that they had adhered to these instructions. Participants had not previously been enrolled in stress-related research and were unfamiliar with each other. Between December 2011 and June 2013, participants were recruited through flyers at general hospitals, psychiatric institutions, and patient associations. Siblings (n=27) were not related to BD1 participants (n=49). Healthy controls (n=48) were matched based on age and gender. The study was approved by the Utrecht Medical Center ethical review board and performed according to the ICH guidelines for Good Clinical Practice and the Declaration of Helsinki and its latest amendments. All participants gave their written informed consent prior to their inclusion in the study and were financially compensated.
Clinical characteristics and drug use
On the day of testing lifetime DSM-IV diagnoses in unaffected siblings and healthy controls group were assessed with the Mini International Neuropsychiatric Interview (MINI) plus (Sheehan et al., 1998) . For all BD1 participants clinical characteristics including BD1 diagnosis, comorbid psychiatric diagnosis, number of manic and depressed episodes, and age of disease onset were established with the Structured Clinical Interview for DSM-IV (SCID) (First et al., 2002) . The interviews were conducted by at least one well-trained independent rater.
Just before the experiments euthymic mood status in BD1 patients was confirmed using the 30-item Inventory of Depressive Symptomatology (IDS-C 30 , range 0-24 ) and Young Mania Rating Scales (YMRS, range 0-7 (Tohen et al., 2000; Young et al., 1978) ) interviews. Participation was postponed if participants scored above predefined cut off values on the YMRS (above 12) or IDS-C 30 (above 24). Based on these criteria, 2 participants were rescheduled for a different test day.
Current use of psychoactive substances (amphetamines, MDMA, barbiturates, cannabinoids, benzodiazepines, cocaine, and opiates) was determined with a urine multi-drug screening device (InstantView) and self-report questionnaire. All participants reporting psychiatric medication use (antidepressants, benzodiazepines, anticonvulsants and antipsychotics), were on a stable (at least one month) dosing schedule. Benzodiazepine use was confirmed by the urine screen. The dose of antipsychotics was transformed to chlorpromazine (CPZ) equivalents as previously described (Woods, 2003) .If participants smoked daily, they were defined as a smoker. Furthermore, female participants were explicitly asked for information about their menstrual cycle and contraceptive medication use as this can influence HPA axis activity (Kirschbaum et al., 1999) .
Four participants (3 controls and 1 BD1 patient) scored positive for cannabis use. Exclusion of the cannabis users did not change any of the results. Four participants (3 BD1 patients and 1 sibling of BD1 patient) taking beta blockers for high blood pressure were excluded from alpha-amylase analysis as its use impairs the alpha-amylase response (van Stegeren et al., 2006) . Since beta blocker use does not affect the cortisol stress response (Kudielka et al., 2007) , participants (N=4) taking beta blockers were included for cortisol analysis. Nevertheless, exclusion of these participants did not change any of the cortisol results.
Procedures
2.3.1. General Participants were tested between 1300 h and 1700 h to control for diurnal variations of cortisol secretion. Participants completed an individual assessment of current mood and symptomology based on psychiatric diagnostic interviews (see paragraph Clinical characteristics and drug use). Participants were instructed not to communicate with each other before being escorted to a waiting area. Ten minutes prior to the TSST-G, participants received instructions and subsequently completed the (TSST-G) task as previously described (Vinkers et al., 2013) . In short, participants were instructed to carry out a public speaking test and subsequently perform an arrhythmic task. All participants were called upon in random order.
Saliva samples
Saliva was collected using salivettes (Sarstedt, Nümbrecht, Germany) for analysis of cortisol and alpha-amylase levels. In total, eight saliva samples were collected in each subject over a 90 min time period (Fig. 1 ). Samples were directly stored at À 80 1C and analyzed as previously described (Vinkers et al., 2013) . In short, cortisol was measured without extraction using an in house competitive radioimmunoassay, and alpha-amylase was measured using a BeckmanCoulter AU5811 chemistry analyzer. If one (out of 8) saliva samples was missing, the missing value was obtained by averaging the surrounding data points. This procedure was used for ten participants (4 controls, 2 siblings and 4 BD1 patients). Exclusion of these 10 participants altogether from the analyses did not alter any of the results. Three participants (2 controls and 1 BD1 patient) were excluded because more than one of the eight salivettes did not contain enough saliva for analysis.
Questionnaires
Perceived levels of stress and anxiety were repeatedly assessed at baseline (t= À 10 min) and during the stress test (t= +8 min) using visual analog scales (VAS, 118 mm scale) ( Figure 1 ). Moreover, previous exposure to traumatic stress influences stress reactivity (Carpenter et al., 2007; Heim et al., 2000; Lovallo et al., 2012) , therefore exposure to childhood maltreatment (Childhood Trauma Questionnaire (CTQ) (Bernstein et al., 2003) and major life events (Lifetime Stressor Checklist-Revised (LSC-R) (Wolfe et al., (1996) ) the Dutch version as previously used (Vinkers et al., 2014) ) were investigated with questionnaires in all participants.
Statistical analyses
All statistics were carried out using SPSS version 20 (SPSS Inc., Chicago, IL, USA). One way ANOVAs were used to analyze differences in baseline parameters between groups. When applicable, Bonferroni post-hoc analysis was performed. If the assumption of homogeneity of variance was violated, Welch's F test was performed followed up with a Games-Howell post-hoc analysis (indicated by non-integerF values). In the case of significant baseline differences in childhood maltreatment, major life events, menopausal status, contraceptive medication use, cannabis use or smoking status, main analyses were performed both with and without these indicators as covariate. Changes in subjective stress rating (VAS during the stress task -VAS baseline) were analyzed using a one way ANOVA with group (control, sibling or BD1) as between-subject factor. Cortisol and alpha-amylase levels were analyzed using repeated measures ANOVA with group (control/sibling/BD1) and sex as between-subject factor and age as a covariate. Sex and age were included in the model as both parameters have been reported to influence cortisol and alpha-amylase levels (Nater et al., 2013) . Planned follow up analysis consisted of comparing BD1 patients to controls and BD1 patients to siblings. Results were corrected by the more stringent Greenhouse-Geisser procedure where appropriate (indicated by an ε value). If there was a significant effect in the repeated measures analysis, data were analyzed per time point using a one-way ANOVA with group (control, sibling or BD1) as between-subject factor.
Furthermore in a stratified analysis of the BD1 group, medication use and clinical characteristics (age of onset, number of manic and depressed episodes and comorbid psychiatric diagnosis) were added as covariates to the repeated measure model. For medication use, lithium (dose in mgs), antidepressant use (yes/no), benzodiazepine use (yes/no), anticonvulsant use (yes/no), and antipsychotic use (yes/no) were used as separate indicators in a single model. Pearson's correlations were used to investigate the relation between medication use and clinical characteristics. If there was a significant correlation between a clinical characteristic and medication use, these measures were both included in the repeated measures model. The significance level was set at Po0.05. All results are presented as average and standard error of the mean.
Results
Lifetime psychiatric disorders and current mood status
Four healthy controls met criteria for a lifetime but not current psychiatric disorder and had recovered completely without professional help: alcohol/drug abuse (n = 3) and agoraphobia (n = 1). Exclusion of these four participants with a history of a psychiatric disorder did not alter any of the results (data not shown). A total of nine siblings met criteria for a previous depressive episode, of which 5 experienced recurrent depressive episodes (and 4 of these 5 participants used antidepressants at the time of participation). Three of the siblings who met the criteria for a previous depressive disorder, also had a comorbid anxiety (n= 2) or alcohol abuse (n = 1) diagnosis.
The BD1 diagnosis was confirmed in all recruited BD1 patients. On the experimental day, current mood in the BD1 patients was euthymic as determined by the YMRS (average 1.2, range 0-7) and IDS-C 30 (average 5.3, range 0-24). Other clinical characteristics collected in the BD1 sample were: number of episodes (average 6.4, range 1-25), age of onset (average 26.6, range 7-60) and comorbid disorders. Nine patients (18%) had either a comorbid anxiety (n= 7) or obsessive compulsive (n = 2) disorder.
Baseline characteristics
Age, sex, contraceptive use and cannabis use did not significantly differ between controls and BD1 patients. The BD1 siblings group contained significantly more females, had a higher average age, and a lower number of smokers compared to the other groups ( 
Childhood trauma and major life events
Siblings and BD1 patients reported more stressful life events compared to controls (LSC-R effect F 2, 123 =7.4 p=0.001; post-hoc: BD1-control p=0.004 and sibling-control p=0.005). In contrast, childhood trauma levels were comparable across all groups (CTQ effect F 2, 123 =1.3 p=0.27). Inclusion of LSC-R as covariate had no effect on any significance level in the current study and was not included in subsequent analyses.
Perceived stress levels
Basal subjective stress ratings were comparable between healthy controls (mean 1.7472.3), siblings of BD1 patients (mean 1.7671.9), and BD1 patients (mean 2.3672.4) (F 2,123 = 1.014 p= 0.37). Moreover, in response to stress, there was a similar increase in subjective stress levels across all groups (F 2, 121 = 1.2 p =0.292).
Cortisol
Groups differed in the endocrine stress response (group effect F 2, 116 =6.2 p=0.003; time x group interaction F 14, 742 =3.2 p=0.010 ε=0.317; see Fig. 2 ). Planned follow up analysis revealed that this difference resulted from a significantly blunted cortisol responses in BD1 patients (BD1-control time x group F 7, 588 =4.6 p=0.008 ε=0.324). Post-hoc analysis confirmed significant different cortisol levels between BD1 patients and controls from 20 min after TSST-G until the end of measurement (t=90 min) (po0.05). Siblings showed a similar cortisol stress response as healthy controls (Siblingcontrol: time x group F 7, 476 =2.2 p=0.111; ε=0.298). As expected, women exhibited an overall blunted cortisol stress response compared to men (sex effect F 1, 116 =9.6 p=0.002; time x sex interaction F 7, 472 =3.7 p=0.021 ε=0.317). A similar sex effect was found after exclusion of women who used contraceptives (sex effect F 1, 109 =9.4 p=0.003; time x sex interaction F 7, 763 =3.7 p=0.026 ε=0.302).
Alpha-amylase
Stress-induced alpha-amylase levels differed between groups over time (group effect F 2, 114 =5.7 p=0.004; time x group interaction F 14, 798 =3.6 p=0.004 ε=0.353; see Fig. 3 ). Planned follow up analysis showed that this difference originated from a significantly increased alpha-amylase response in BD1 patients (BD1-control time x group interaction F 7, 609 =7.1 po0.001 ε=0.322). Significant differences were present between BD1 patients and healthy controls during all time points (po0.05) except at t=80 min (p=0.076). In contrast, the alpha-amylase stress response of siblings was not significantly different from the alpha-amylase stress response in healthy controls (Sibling vs.-control: time x group interaction F 7, 469 =1.6 p=0.170 ε=0.452). No significant sex effects or interactions were found (sex effect F 1, 114 =0.4 p=0.842, time x sex F 7, 472 =0.2p=0.846 ε=0.353). The alpha-amylase stress response was enhanced in older participants independent of group status (age effect F 1, 114 =8.5 p=0.004; time x age F 7, 472 =2.9 p=0.044 ε=0.353).
Medication
All BD1 patients used medication, most commonly lithium (69%) and antipsychotics (61%, average CPZ equivalent 112.8 mg), followed by anticonvulsants (28%), antidepressants (20%), and benzodiazepines (14% Fig. 4 ). This antipsychotic effect was specific for stress-induced cortisol fluctuations over time since there was no significant main effect of antipsychotic use on overall or basal cortisol levels in the BD1 group (F 1, 45 =2.8 p=0.100). Moreover, CPZ equivalents showed similar blunted stress-induced cortisol responses in BD1 patients (time n CPZ F 7, 315 =5.8 p=0.002 ε=0.350). Antipsychotic use was not significantly associated with either overall or time-dependent levels of stressinduced alpha-amylase (all p values 40.17). No significant correlations were found between antipsychotic use (CPZ equivalents) and clinical characteristics (number of episodes r= À0.008 p=0.960; age of onset r= À 0.038 p=0.813), therefore clinical characteristics were not used as a covariate in the analysis of antipsychotics.
Clinical BD1 disease parameters
The number of previous mood episodes was significantly associated with overall decreased cortisol levels in BD1 patients independent of stress exposure (episode effect F 1, 37 =6.6, p=0.014; see Figure 4 ). In contrast, no significant effect of number of previous mood episodes was seen on the stress-induced cortisol response (time Â episodes interaction F 7, 259 =1.1 p=0.313 ε =0.381). For graphical representation, number of episodes were divided with a median split in high (45) and low (r5) number of episodes. Age of onset (all p values40.26) and comorbid psychiatric diagnosis (all p values40.19) had no significant effect on either cortisol or alpha amylase levels.
Discussion
We found that in response to stress, euthymic BD1 patients perceived similar stress levels as healthy controls but displayed a blunted cortisol response and increased alphaamylase levels. This blunted cortisol response is in line with a recent study that investigated 13 euthymic female BD1 patients (Wieck et al., 2013) . A striking finding of the current study is that antipsychotic use was the most important factor associated with the reduced cortisol stress response in BD1 patients, accounting for most of the differences between stress-induced cortisol levels in BD1 patients and healthy controls. After inclusion of antipsychotic use as a covariate, the blunted cortisol stress response in BD1 patients no longer significantly differed from the one in healthy controls. To our knowledge, this is the first study to show that antipsychotic use plays an important role in endocrine stress reactivity. Studies investigating stress reactivity in schizophrenia have consistently found a blunted cortisol stress response (Jansen et al., 1998; Jansen et al., 2000; Ritsner et al., 2005) , and antipsychotics have been implicated in this attenuated cortisol response (Brenner et al., 2009) . In support, the majority of studies found reduced baseline cortisol levels in schizophrenia patients who used antipsychotics (for review see (Walker et al., 2008) ), and increased cortisol levels are a predictor Figure 2 The effect of the TSST-G on a-amylase levels in saliva of BD1 patients, unaffected siblings, and healthy controls. n: po0.05; #: po0.10. Figure 3 The effect of antipsychotic use on the cortisol response to the TSST-G in BD1 patients. The cortisol response of healthy controls is added for graphical comparison only and was not used in the statistical model. n: po0.05; #: po0.10. Figure 4 Number of mood episode (more or less than 5) on the cortisol stress response in BD1 patients. The cortisol response of healthy controls is added for graphical comparison only and was not used in the statistical model. n: po0.05.
of antipsychotic treatment effects in schizophrenia (Ritsner et al., 2005 ). An advantage of studying the effects of antipsychotic use in BD1 patients is that -in contrast to schizophrenia patients -not all patients use antipsychotics. This enabled the direct comparison of the stress response between euthymic BD1 patients that use antipsychotics and those who do not. In our BD1 sample use of antipsychotics was not correlated to clinical characteristics, such as age of onset or number of manic and depressed episodes, indicating the blunted stress induced cortisol response in the antipsychotic group is not related to these clinical characteristics. Our data raise the question whether blunted cortisol response in BD1 disorder and schizophrenia may be only the result of antipsychotic drug use. This seems unlikely, since a blunted cortisol response was also present in medication naïve first episode psychotic patients (van Venrooij et al., 2012) .
In contrast to the use of antipsychotics, use of lithium, anticonvulsants, benzodiazepines, and antidepressants did not significantly affect the endocrine and autonomic stress response in our sample. Even though acute administration of alprazolam or lamotrigine results in blunted stress-induced cortisol levels in healthy controls (Fries et al., 2006; Kudielka et al., 2007; Maheu et al., 2005; Makatsori et al., 2004; Walker et al., 2008) , such effects were not always detected (Lange et al., 2013; Watson et al., 2004; Roelofs et al., 2009) . The chronic use of psychiatric medication in BD1 patients or the limited statistical power due to a rather small sample size may also have contributed to the fact that we found no significant effects for most medication groups in our study.
No significant effect was found of either age of onset or comorbid psychiatric disorders in BD1 patients. Nevertheless, an increased number of previous mood episodes was associated with overall reduced cortisol levels independent of stress. This adjustment of basal HPA axis activity after an increasing number of mood episodes is in line with the kindling hypothesis (Post, 1992) , which suggests that during initial affective episodes, alterations in stress related systems occur which lead to an increased risk to develop subsequent mood episodes independent of stressors (for a recent review of the kindling hypothesis in BD1 see (Bender and Alloy, 2011) ).
Traumatic stress plays an important role in the etiology and course of BD1 (Proudfoot et al., 2011) and also affects stress reactivity (Heim et al., 2000; Nater et al., 2007; van Winkel et al., 2013) . Nevertheless, our data do not support a role for traumatic stress exposure or major life events on the acute stress response in BD1 patients. First, childhood maltreatment was similar across the experimental groups and the number of reported major life events was comparable between siblings and BD1 patients. Thus, even though levels of traumatic stress or major life events were comparable, differences were present in the endocrine and autonomic stress response in BD1 patients compared to healthy controls and siblings, respectively. Moreover, adding traumatic stress scores or major life events as a covariate did not change any of the results.
Previous studies have reported increased basal cortisol levels in healthy offspring of BD1 patients (Ostiguy et al., 2011) , indicating that a genetic predisposition for BD1 may result in alterations in HPA axis functionality. However, we found no indication of changes in stress-induced cortisol and alpha-amylase levels in unaffected siblings of BD1 patients.
Therefore, this study supports and extends an earlier study in which young offspring (age 13-21) displayed a similar cortisol stress response compared to healthy controls (Ellenbogen et al., 2006) . In light of these data, an intermediate stress reactivity phenotype in unaffected siblings of BD1 patients is not likely.
Our findings should be interpreted in light of the existing data on HPA-axis activity in bipolar disorder. Several studies in which the HPA-axis was pharmacologically challenged showed that there is a reduced negative feedback in bipolar disorder patients, associated with hypercortisolism (Watson et al., 2004; Rybakowski and Twardowska, 1999; Schmider et al., 1995) . This disrupted feedback has further been related to decreased glucocorticoid receptor (GR) sensitivity in bi polar disorder (for review see (Spijker et al., 2011) ). Reduced negative feedback would be expected to result in elevated basal cortisol levels and enhanced cortisol response after stress. Since we did not use any HPA-axis related pharmacological intervention, our data can only indirectly assess feedback and GR sensitivity. Nevertheless, from our data there is no indication for a reduced negative feedback in patients with bipolar disorder, as basal cortisol levels were unaffected and there was an overall blunted cortisol stress response. A possible explanation for the blunted cortisol stress response is chronic exposure to increased cortisol levels that gradually decrease the dynamic capacity of the HPA-axis. However, confirmation of this hypothesis would require prospective follow-up of a population with a high-risk for developing bipolar disorder. Importantly, antipsychotic use explained the variation in cortisol stress reactivity in our study to a large extent. This suggests that antipsychotic use rather than bipolar disorder per se may be involved in a gradual blunting of the cortisol response. Finally, in bipolar offspring, basal cortisol levels but not stress-induced cortisol levels were altered (Ellenbogen et al., 2006) , indicating that these cortisol measures cannot be compared directly.
The results of the present study should be interpreted in the context of several potential limitations. First, as a result of the cross-sectional nature of our study, we cannot determine the order of adaptation of the endocrine or autonomic system. A second limitation is that this study was not specifically set up to compare the effects of antipsychotic use in a BD1 population. It is possible that more severely ill and treatment-resistant BD1 patients were included who -as a result -used increased doses of antipsychotic drugs. However, antipsychotic use did not significantly correlate with clinical characteristics such as age of onset, comorbid psychiatric diagnosis, and number of mood episodes. Third, alpha-amylase was included as a measure for autonomic stress reactivity whereas heart rate is a more common readout parameter. Nevertheless, alpha-amylase is a validated autonomic stress marker which consistently correlates to autonomic stress responses and noradrenaline release (Nater and Rohleder, 2009; Rohleder et al., 2004) . Unfortunately, unaffected and unrelated siblings were more difficult to recruit, particularly as a result of daytime jobs, resulting in a smaller sample size compared to the other groups, a significant higher number of female participants and a significant higher age. Although we adjusted for this we cannot rule out residual confounding (Miller and Chapman, 2001) . Strengths of the current study are the relatively large overall sample size, the inclusion of unaffected siblings to investigate a possible genotype effects, inclusion of both male and female participants, and assessment of current and lifetime diagnosis.
In conclusion, the current study shows a blunted cortisol stress response and increased autonomic stress response in euthymic BD1 patients. Our data indicate that antipsychotic use but not genetic loading is the most important determinant of the blunted cortisol stress response in BD1 patients. Even though it remains to be determined whether antipsychotics exert a protective or detrimental role in stressrelated processes in BD1 patients, our findings underscore the possible importance of antipsychotic use on endocrine stress reactivity.
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